Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial
Stanley Evan Cooper(Cornell University), Roy M. Gulick(New York University), Shuaiqi Zhang(Clinical Research Institute), Raphael J. Landovitz(APLA Health), Marybeth McCauley(Family Health International 360), Craig W. Hendrix(Unknown), Wairimu Chege(National Institutes of Health), Mark A. Marzinke(Family Health International 360), Daniel Haines(Fred Hutch Cancer Center), K. Rivet Amico(University of Cape Town), Kenneth H. Mayer(Miriam Hospital)
Cited by 1
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k